WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today ...
Abpro Holdings, Inc., a biotechnology company focused on developing antibody therapies for severe diseases, has announced the departure of CEO Ian Chan. Miles Suk, the Board Chairman, expressed ...
WOBURN, Mass. & NEW YORK--(BUSINESS WIRE)--Abpro Corporation (“Abpro”), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with ...
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results